Document is current
Any future updates will be listed below
-
Authors
Moody, Kevin https://orcid.org/0000-0002-0442-7680
Smit, Colette https://orcid.org/0000-0003-3241-8439
Nieuwkerk, Pythia T. https://orcid.org/0000-0002-2616-1414
Bedert, Maarten https://orcid.org/0000-0002-5899-0663
Nelis, Elise
Nellen, Jeannine https://orcid.org/0000-0001-8176-8027
Sigaloff, Kim https://orcid.org/0000-0001-6754-3809
Weijsenfeld, Annouschka https://orcid.org/0009-0002-6660-5208
Laan, Laura
Bruins, Claire
Geerlings, Suzanne E. https://orcid.org/0000-0002-8518-3576
van der Valk, Marc https://orcid.org/0000-0002-8290-6425
-
Funding
Funding for this research was provided by:
Gilead Sciences (n/a)
Agency for Healthcare Research and Quality (n/a)
- License Information
-
More Information
Article History
Accepted: 4 January 2025
First Online: 27 January 2025
Declarations
:
: Participants consented to participate in the analysis of data collected as part of routine clinical care to the AIDS Therapy Evaluation in the Netherlands study (ATHENA) cohort through mechanisms described in Boender et al. (BMJ Open. 2018;8(9):e022516. ). Additional ethical approval for the analysis of these data was not required under the ATHENA cohort protocol.
: KM has received fees for educational activities from Springer Media and Gilead Sciences. FJBN has received fees for educational activities from Virology Education, Gilead, ViiV Healthcare, MSD and Astra Zeneca and fees for participation in scientific advisory boards from Gilead Sciences, ViiV Healthcare, MSD and Astra Zeneca all paid to her institution. MvdV has received unrestricted research funding from ViiV, Gilead and MSD and fees for participation in scientific advisory boards from ViiV, Gilead Sciences and MSD all paid to his institution.
